Celecoxib: A specific COX-2 inhibitor with anticancer properties

Cancer Control

Volumn 9, Issue 2 SUPPL., 2002, Pages 28-35

  Koki, Alane T ^a   Masferrer, Jaime L ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOGENESIS INHIBITOR; AROMATASE INHIBITOR; AZOXYMETHANE; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; DIMETHYLBENZ[A]ANTHRACENE; EXEMESTANE; IBUPROFEN; NONSTEROID ANTIINFLAMMATORY AGENT;

ANIMAL MODEL; BREAST CANCER; CANCER INCIDENCE; CANCER PREVENTION; COLORECTAL TUMOR; CONTROLLED STUDY; DOSE RESPONSE; DRUG INDUCED DISEASE; ENZYME INHIBITION; FEMALE; GASTROINTESTINAL TOXICITY; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; NEPHROTOXICITY; NONHUMAN; ONCOGENE NEU; PARTIAL MASTECTOMY; PROGNOSIS; RAT; REVIEW; SOLID TUMOR; TUMOR GROWTH; TUMOR VOLUME;

EID: 0036236186     PISSN: 10732748     EISSN: None     Source Type: Journal    
DOI: 10.1177/107327480200902s04     Document Type: Review

References (106)

1. Rapid and transient induction of cyclooxygenase 2 by epidermal growth factor in human amnion-derived WISH cells
2. Differential regulation of cyclooxygenases 1 and 2 by interleukin-1 beta, tumor necrosis factor-alpha, and transforming growth factor-beta 1 in human lung fibroblasts
3. Transcriptional activation of cyclooxygenase-2 in Wnt-1 transformed mouse mammary epithelial cells
4. Regulation of the cyclooygenas-2 pathway by HER2 receptor
5. COX-1 and COX-2 tissue expression: Implications and predictions
6. Potential utility of COX-2 inhibitors in chemoprevention and chemotherapy
7. The role of cyclooxygenases in inflammation, cancer, and development
8. A guideline for the treatment and prevention of NSAID-induced ulcers
9. NSAID induced gastrointestinal complications: The ARAMIS perspective - 1997
10. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: The CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study
11. Incidence of cancer among patients with rheumatoid arthritis
12. Aspirin use, cancer, and polyps of the large bowel
13. A hypothesis: Nonsteroidal anti-inflammatory drugs reduce the incidence of large bowel cancer
14. Aspirin and nonsteroidal anti-inflammatory drug use and the risk of subsequent colorectal cancer
15. Nonsteroidal anti-inflammatory drugs and colorectal cancer
16. Non-steroidal anti-inflammatory drugs and the chemoprevention of colorectal and oesophageal cancers
17. Aspirin use and the risk of fatal cancer
18. Nonsteroidal anti-inflammatory drug use and protection against colorectal cancer in women
19. Aspirin use and lung, colon, and breast cancer incidence in a prospective study
20. Nonsteroidal anti-inflammatory drugs and breast cancer
21. Epidemiological study of non-steroidal anti-inflammatory drugs and breast cancer
22. Prospective study of nonsteroidal anti-inflammatory drugs and breast cancer
23. NSAID use and decreased risk of gastrointestinal cancers
24. Use of aspirin and other nonsteroidal anti-inflammatory drugs and risk of esophageal and gastric cancer
25. Aspirin and reduced risk of esophageal carcinoma
26. COX-2 is expressed in human pulmonary, colonic, and mammary tumors
27. COX-2 expression is induced by UVB exposure in human skin: Implications for the development of skin cancer
28. Increased cyclooxygenase-2 expression in human pancreatic carcinomas and cell lines: Growth inhibition by nonsteroidal anti-inflammatory drugs
29. Overexpression of cyclooxygenase-2 in squamous cell carcinoma of the urinary bladder
30. Overexpression of cyclooxygenase-2 in carcinoma of the pancreas
31. Cyclooxygenase-2 expression in human esophageal carcinoma
32. Expression of cyclooxygenase-2 in prostate carcinoma
33. Cox-2 expression in retinoblastoma
34. Cyclooxygenase-2 expression in hepatocellular carcinoma
35. Expression of cyclooxygenase-2 (COX-2) in human invasive transitional cell carcinoma (TCC) of the urinary bladder
36. Cyclooxygenase-2 is overexpressed in human cervical cancer
37. Cyclooxygenase-2 expression is up-regulated in squamous cell carcinoma of the head and neck
38. Cyclooxygenase-2 expression is up-regulated in human pancreatic cancer
39. Prostaglandin and breast cancer
40. Prostacyclin and thromboxane in benign and malignant breast tumors
41. Cyclooxygenase-2 gene expression in human breast cancer
42. Cyclooxygenase-2 overexpression correlates with tumour recurrence, especially haematogenous metastasis, of colorectal cancer
43. Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential
44. Tumor invasiveness and liver metastasis of colon cancer cells correlated with cyclooxygenase-2 (COX-2) expression and inhibited by a COX-2-selective inhibitor, etodolac
45. Cyclooxygenase-2 overexpression enhances lymphatic invasion and metastasis in human gastric carcinoma
46. Clinicopathologic association of cyclooxygenase 1 and cyclooxygenase 2 expression in gastric adenocarcinoma
47. Prognostic significance of elevated cyclooxygenase 2 expression in primary, resected lung adenocarcinomas
48. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene
49. Increased expression of cyclooxygenase-2 in HER-2/neu overexpressing human breast cancer cells
50. Characterization of cyclooxygenase-2 (COX-2) expression and Her2/neu in human breast, colon, and prostate cancer
51. Cyclooxygenase-2 (COX-2) is co-localized with HER-2/neu in human breast cancer
52. Cyclooxygenase-2: A target for the prevention and treatment of breast cancer
53. Cyclooxygenase-2 inhibition by celecoxib reduces proliferation and induces apoptosis in angiogenic endothelial cells in vivo
54. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors
55. Role of cyclooxygenases in angiogenesis
56. Inhibition of cyclooxygenase-2 suppresses angiogenesis and the growth of prostate cancer in vivo
57. Selective inhibition of cyclooxygenase-2 suppresses growth and induces apoptosis in human esophageal adenocarcinoma cells
58. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2
59. Blockade of cyclooxygenase-2 inhibits proliferation and induces apoptosis in human pancreatic cancer cells
60. The cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking Akt activation in human prostate cancer cells independently of Bcl-2
61. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis
62. Hypoxia regulates vascular endothelial growth factor gene expression in endothelial cells
63. A hypoxia-responsive element mediates a novel pathway of activation of the inducible nitric oxide synthase promoter
64. Induction of interleukin 6 (IL-6) by hypoxia in vascular cells. Central role of the binding site for nuclear factor-IL-6
65. Hypoxic induction of interleukin-8 gene expression in human endothelial cells
66. Endothelial PAS domain protein I (EPAS1), a transcription factor selectively expressed in endothelial cells
67. Role of arachidonic acid metabolism in the mitogenic response of BALB/c 3T3 fibroblasts to epidermal growth factor
68. Early cell cycle diacylglycerol (DAG) content and protein kinase C (PKC) activity enhancement potentiates prostaglandin F2 alpha (PGF2 alpha) induced mitogenesis in Swiss 3T3 cells
69. Prostaglandin F2 alpha-induced mitogenesis in MC3T3-E1 osteoblasts: Role of protein kinase-C-mediated tyrosine phophorylation
70. Linoleate metabolites enhance the in vitro proliferative response of mouse mammary epithelial cells to epidermal growth factor
71. Lung cancer cyclooxygenase-2 dependent inhibition of dendritic cell maturation and function
72. Non-small cell lung cancer-derived soluble mediators and prostaglandin E2 enhance peripheral blood lymphocyte IL-10 transcription and protein production
73. Aspirin and the potential role of prostaglandins in colon cancer
74. Carcinogen substrate specificity of human COX-1 and COX-2
75. Estrogen biosynthesis proximal to a breast tumor is stimulated by PGE2 via cyclic AMP, leading to activation of promoter II of the CYP 19 (aromatase) gene
76. Inhibition of tumor necrosis factor alpha-stimulated aromatase activity by microtubule-stabilizing agents, paclitaxel and 2-methoxy-estradiol
77. Genetic induction and upregulation of cyclooxygenase (COX) and aromatase (CYP19): An extension of the dietary fat hypothesis of breast cancer
78. Correlation of aromatase and cyclooxygenase gene expression in human breast cancer specimens
79. Tumor angiogenesis: Therapeutic implications
80. Quantitative relationships of intravascular tumor cells, tumor vessels, and pulmonary metastases following tumor implantation
81. Ibuprofen-induced inhibition of cyclooxygenase isoform gene expression and regression of rat mammary carcinomas
82. Modulation of rat mammary carcinogenesis by indomethacin
83. Comparative chemopreventive activity of ibuprofen and N-(4-hydroxyphenyl) retinamide against the development and growth of rat mammary adenocarcinomas
84. Inhibition of human colon cancer cell growth by selective inhibition of cylcooxygenase-2
85. Cyclooxygenase-2 inhibitors suppress the growth of gastric cancer xenografts via induction of apoptosis in nude mice
86. Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2)
87. Chemoprevention of colon cancer by specific cyclooxygenase-2 inhibitor, celecoxib, administered during different stages of carcinogenesis
88. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis
89. Celecoxib prevents tumor growth in vivo without toxicity to normal gut: Lack of correlation between in vitro and in vivo models
90. The cyclooxygenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in the min mouse model of adenomatous polyposis
91. Topical application of a selective cyclooxygenase inhibitor, celecoxib, suppresses UVB-mediated cutaneous inflammation
92. Reduction of UV-induced skin tumors in hairless mice by selective COX-2 inhibition
93. Celecoxib inhibits N-butyl-N-(4-hydroxybutyl)-nitrosamine-induced urinary bladder cancers in male B6D2F1 mice and female Fischer-344 rats
94. Chemoprevention of breast cancer in rats by celecoxib, a cyclooxygenase 2 inhibitor
95. Chemotherapeutic evaluation of Celecoxib, a cyclooxygenase-2 inhibitor, in a rat mammary tumor model
96. Evaluation of cyclooxygenase-2 inhibitor for potential chemopreventive properties in colon carcinogenesis
97. Dose-response effects of the COX-2 inhibitor, celecoxib, on the chemoprevention of mammary carcinogenesis
98. Relative chemopreventive efficacy of the COX-2 inhibitor, celecoxib, on the initiation and promotion phases of rat mammary carcinogenesis
99. Effect of exemestane and celecoxib alone or in combination on DMBA-induced mammary carcinoma in rats
100. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity
101. Preclinical studies of the combination of angiogenic inhibitors with cytotoxic agents
102. COX-2 inhibitor enhances tumor radioresponse in vitro and in vivo
103. Enhancement of tumor response to gamma-radiation by an inhibitor of cyclooxygenase-2 enzyme
104. Inhibitors of prostaglandin synthesis inhibit human prostate tumor cell invasiveness and reduce the release of matrix metalloproteinases
105. Aspirin and the potential role of prostaglandins in colon cancer
106. Celecoxib: A specific cyclooxygenas-2 (COX-2) inhibitor with antiangiogenic and anticancer activities